Noah Eisenberg's questions to IGM Biosciences (IGMS) leadership • Q4 2022
Question
Noah Eisenberg of JPMorgan Chase & Co. asked about the potential for synergistic combinations of IGM-8444 with EGFR or KRAS inhibitors, given the trial's stratification by KRAS status.
Answer
Chief Medical Officer Dr. Chris Takimoto and Chief Scientific Officer Dr. Bruce Keyt responded that they expect IGM-8444 to be active across various molecular subtypes, including KRAS mutant and wild-type. While the current strategy is to develop the drug broadly, they are open to exploring combinations with agents like EGFR inhibitors in the future and are currently investigating these possibilities pre-clinically.